Explore cagrilintide calculator-entry dose, vial-size, BAC-water and self-reported frequency distributions. Research context is separate from live observations.
Anonymized cagrilintide calculator entries are summarized by each chart's selected period. Frequency responses come from the separate vial-duration feature. Inputs are not verified administrations or unique people.
Cagrilintide is a long-acting amylin-analog research peptide most often sourced for weight-management research, frequently paired with semaglutide. It ships as a lyophilized powder you reconstitute with bacteriostatic water before use.[1]
Amylin is co-secreted with insulin by pancreatic beta cells and acts on AMY1, AMY2, and AMY3 receptors (calcitonin receptor heterodimers with RAMP1/2/3) in the area postrema and hypothalamic arcuate nucleus to slow gastric emptying, suppress glucagon, and reduce food intake via central satiety pathways. Cagrilintide uses a fatty-acid side-chain to enable albumin binding and extends amylin's half-life from minutes to roughly 159 hours, supporting once-weekly dosing.[2]
A 26-week Phase 2 trial (Lau et al., Lancet 2021) in 706 adults with obesity reported ~10.8% mean weight reduction on cagrilintide 4.5mg monotherapy versus 3.0% on placebo.[2] A Phase 1b combination study with semaglutide (Enebo et al., Lancet 2021) found ~17.1% weight loss at 20 weeks — driving the move to the REDEFINE Phase 3 program comparing CagriSema head-to-head against tirzepatide.[3]
Not FDA-approved. Phase 3 REDEFINE program ongoing as the CagriSema (cagrilintide + semaglutide) fixed combination. Cagrilintide monotherapy is not in active development.
Cagrilintide has a reported half-life of ~7 days. The pharmacokinetic reference models an interval of once weekly; this is not a measured community cadence or a dosing recommendation. Long-acting amylin analog designed for once-weekly dosing; it reaches a steady level over about 5 weeks, with a lot carrying over week to week. Pharmacokinetic source: Lau et al. (Novo Nordisk) Phase 1 cagrilintide / AM833 pharmacokinetics. It is catalogued under Weight Loss on WPA.
2,746 Cagrilintide reconstitution calculations have been logged by the WPA community.
This is the lifetime header population. Each chart and its associated analysis below use their own selected period and denominator; frequency responses are a separate cohort.
These figures come from anonymized WPA peptide calculator sessions, not verified administrations or unique people. Separate modal inputs do not establish a joint protocol. They are community input statistics — not dosing recommendations, and not medical advice.
WPA Analysis
Cagrilintide is a long-acting amylin analog engineered by Novo Nordisk — a modified human amylin sequence with a fatty-acid spacer at Lys26 that pushes the half-life out to roughly 159 hours and supports weekly subcutaneous dosing, which native amylin (and its short-acting analog pramlintide) cannot. The published clinical record for cagrilintide as a standalone molecule is anchored almost entirely in Lau et al., Lancet 2021, the phase 1b/2 dose-finding program that enrolled 706 adults with overweight or obesity and tested cagrilintide arms at 0.3, 0.6, 1.2, 2.4, and 4.5mg once weekly against liraglutide 3.0mg/day and placebo. The 4.5mg arm produced a mean weight reduction of about 10.8% at 26 weeks versus roughly 3% on placebo — a respectable signal for a single-mechanism amylin agonist, but never the headline figure cagrilintide is now best known for. That figure comes from the combination program: CagriSema, a fixed-dose pairing of 2.4mg cagrilintide and 2.4mg semaglutide, which is the entire focus of the Phase 3 REDEFINE series (REDEFINE 1 in obesity, REDEFINE 2 in type 2 diabetes, REDEFINE 4 head-to-head against tirzepatide). REDEFINE 1 read out in late 2024 / early 2025 with a mean weight reduction of about 22.7% at 68 weeks. The structural fact worth noting is that cagrilintide alone has never been advanced toward approval as a standalone product; every active phase 3 program pairs it with semaglutide, and the published rationale for that pairing is mechanistic complementarity — amylin signaling adds a satiety / gastric-emptying pathway that GLP-1 agonism does not directly engage.
Research background is separate from the calculator observations below. Calculator entries do not establish administration, safety, effectiveness, or the reasons for an input.
WPA DOSING INSIGHT
The summaries use each chart's own period and, for frequency responses, its dose filter. Separate cohorts must not be combined into a protocol.
WPA RECONSTITUTION INSIGHT
Vial-size and BAC-water observations describe separate input distributions, not purchases or verified preparations. Separate modal inputs do not establish a joint protocol.
These figures come from anonymized WPA peptide calculator sessions.
All figures shown are aggregated from anonymized calculator inputs and are provided strictly for independent laboratory research and educational purposes. They are community usage statistics — not dosing recommendations, and not medical advice.